As of March 31, 2020, we account for our investment in Ceridian at fair value pursuant to ASC 321. We recorded unrealized gains of $684.9 million upon the change in accounting all of which relates to Ceridian equity securities which continue to be held by the Company as of March 31, 2020. The unrealized gain is included in Realized and other gains and losses, net on the Condensed Consolidated Statement of Operations for the three months ended March 31, 2020.

Investments in unconsolidated affiliates recorded using the equity method of accounting as of March 31, 2020 and December 31, 2019 consisted of the following (in millions):



	Ownership at March 31, 2020		March 31, 2020		December 31, 2019
Dun & Bradstreet	24.3	%	$	396.5	$	385.9
Ceridian (1)	13.7	%	—		309.5
Equity Fund	49.0	%	134.3		46.7
AmeriLife	20.3	%	125.0		—
Other	various		103.4		94.4
Total			$	759.2	$	836.5

Equity in earnings (losses) of unconsolidated affiliates for the three months ended March 31, 2020 and March 31, 2019 consisted of the following (in millions):



	Three months ended March 31, 2020			Three months ended March 31, 2019
Dun & Bradstreet	$	10.1		$	(24.3	)
Ceridian (1)	1.5			2.6
Equity Fund	(58.8		)	—
AmeriLife	—			—
Other	(5.5		)	0.3
Total	$	(52.7	)	$	(21.4	)

(1) Fiscal year 2020 amount represents the Company's equity in earnings of Ceridian in the three months ended March 31, 2020 prior to the change in accounting for the investment as of March 31, 2020.

Summarized financial information for Dun & Bradstreet for the relevant dates and time periods included in Investments in unconsolidated affiliates and Equity in earnings (losses) of unconsolidated affiliates in our Condensed Consolidated Balance Sheets and Statements of Operations, respectively, is presented below.

We acquired our initial interest in Dun & Bradstreet's parent on February 8, 2019. The results of operations for the three months ended March 31, 2019 presented below represents Dun & Bradstreet's results of operations subsequent to our acquisition.



	March 31, 2020		December 31, 2019
	(In millions)
Total current assets	$	570.1	$	417.9
Goodwill and other intangible assets, net	7,994.2		8,091.5
Other assets	608.1		603.4
Total assets	$	9,172.4	$	9,112.8

Current liabilities	$	927.7	$	1,090.4
Long-term debt	4,023.9		3,818.9
Other non-current liabilities	1,568.5		1,594.0
Total liabilities	6,520.1		6,503.3
Preferred equity	1,032.8		1,030.6
Total capital	1,619.5		1,578.9
Total liabilities and equity	$	9,172.4	$	9,112.8



	Three months ended March 31, 2020			Period from February 8, 2019 to March 31, 2019
	(In millions)
Total revenues	$	395.3		$	174.1
Loss before income taxes	(1.0		)	(111.6		)
Net income (loss)	73.9			(81.1		)
Dividends attributable to preferred equity and noncontrolling interest expense	(32.4		)	(18.3		)
Net income (loss) attributable to Dun & Bradstreet	41.5			(99.4		)

As of March 31, 2020, we have invested $192.1 million in the Equity Fund, all of which has been contributed to the fund's capital and is accounted for under the equity method of accounting for investments. Summarized financial information for the Equity Fund for the relevant dates and time periods included in Investments in unconsolidated affiliates and Equity in losses of unconsolidated affiliates in our Condensed Consolidated Balance Sheets and Statements of Operations, respectively, is presented below.



	March 31, 2020		December 31, 2019
	(In millions)
Due from brokers and counterparties	$	393.5	$	93.2
Cash and cash equivalents	—		45.2
Derivative contracts, at fair value	—		2.4
Other assets	0.1		—
Total assets	$	393.6	$	140.8

Derivative contracts, at fair value	$	118.1	$	—
Capital received in advance	—		45.2
Other liabilities	1.4		0.2
Total liabilities	119.5		45.4
Net assets	$	274.1	$	95.4



	Three months ended March 31, 2020
	(In millions)
Total net investment loss	$	(0.3	)
Realized gain on securities and derivative contracts	0.5
Change in unrealized loss on derivative contracts	(120.5		)
Change in net assets from operations	(120.3		)

On March 18, 2020, we closed on our $125.0 million investment in the AmeriLife Joint Venture. We account for our investment in AmeriLife as an equity method investment and report our equity in earnings or loss of the AmeriLife Joint Venture on a three-month lag. Because the Company will record its equity in earnings or loss of the AmeriLife Joint Venture using lag reporting, there is no equity in earnings or loss of AmeriLife included in the Company’s results of operations for the three months ended March 31, 2020. The Company plans to begin including its equity earnings or loss related to AmeriLife in the three months ended June 30, 2020, at which time the Company expects to begin providing summary financial information for the AmeriLife Joint Venture.

We account for our investment in preferred equity of QOMPLX, Inc. ("QOMPLX"), an intelligent decision and analytics platform used by businesses for modeling and planning, at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly market transactions. As of March 31, 2020, we have $22.5 million recorded for our investment in QOMPLX, which is included in Other long term investments and noncurrent assets on our Condensed Consolidated Balance Sheet. We have not recorded any upward or downward adjustments to our investment in QOMPLX.



	March 31, 2020
	Carrying Value		Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(In millions)
Fixed maturity securities available for sale:
Corporate debt securities	$	26.1	$	19.9	$	6.4	$	(0.2	)	$	26.1
Total	$	26.1	$	19.9	$	6.4	$	(0.2	)	$	26.1



	December 31, 2019
	Carrying Value		Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(In millions)
Fixed maturity securities available for sale:
Corporate debt securities	$	19.2	$	19.6	$	0.7	$	(1.1	)	$	19.2
Total	$	19.2	$	19.6	$	0.7	$	(1.1	)	$	19.2

The cost basis of fixed maturity securities available for sale includes an adjustment for amortized premium or discount and other-than-temporary-impairment recognized in earnings since the date of purchase.

As of March 31, 2020, $25.7 million of the fixed maturity securities in our investment portfolio had a maturity of less than one year and $0.4 million had a maturity of greater than one year, but less than five years. Expected maturities may differ from contractual maturities because certain borrowers have the right to call or prepay obligations with or without call or prepayment penalties.

During the three months ended March 31, 2020, we incurred no other-than-temporary impairment charges relating to corporate debt securities. During the three months ended March 31, 2019, we incurred $0.3 million of other-than-temporary impairment charges relating to corporate debt securities which is included in Realized and other gains and losses, net on the Condensed Consolidated Statement of Operations. The impairment recorded relates to a corporate debt holding that had experienced a prolonged period of declining earnings and that we were uncertain of our ability to recover our initial investment. All of the loss represents credit loss recognized in earnings and no portion of the loss was included in other comprehensive earnings.